Back

Notification report


Full notification file


General information

Notification Number
B/NL/16/012

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
13/02/2017

Title of the Project
Clinical evaluation of a live attenuated Respiratory Syncytial Virus (RSV) vaccine based on a genetically modified RSV virus lacking the coding sequence for the attachment protein G

Proposed period of release:
16/04/2018 to 31/12/2030

Name of the Institute(s) or Company(ies)
Leiden University Medical Center, Albinusdreef 2
2333 ZA Leiden
PO Box 9600
2300 RC Leiden
The Netherlands;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
RNA Virus

Identity of the GMO:
Pneumovirus, Respiratory Syncytial virus A

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Human Respiratory Syncytial virusOrthopneumovirusHuman Respiratory Syncytial virusSubtype AClinical isolate RSV 98-25147-Xgenotype GA2

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known